Form 4 for ICUI ICU MEDICAL INC/DE
Accepted 2026-03-09 00:00:00 ET · period of report 2026-03-07 · accession 0001698998-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-09 | 2026-03-07+ | ICUI | Woolson Daniel | VP, GM-Infusion Capital | F - Tax | $132.00 | -8,209 | 21.4K | -28% | -$1.08M |
| DM | 2026-03-09 | 2026-03-07+ | ICUI | Woolson Daniel | VP, GM-Infusion Capital | M - OptEx | $0.00 | +19.9K | 12.9K | New | $0 |
| DM | 2026-03-09 | 2026-03-07+ | ICUI | Woolson Daniel | VP, GM-Infusion Capital | M - OptEx | $0.00 | -19.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-08 | F | D | 630 | $132.00 | 22,973 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-08 | M | A | 2,153 | $0.00 | 23,603 | D | — | — | (F2) These securities are Restricted Stock Units. |
| 3 | Common | Common Stock | 2026-03-07 | F | D | 702 | $132.00 | 12,180 | D | — | — | |
| 4 | Common | Common Stock | 2026-03-08 | M | A | 16,147 | $0.00 | 28,327 | D | — | — | (F1) Represents the settlement of performance stock units granted on 3/8/2024. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 250% of target, resulting in the acquisition of the shares reported herein. |
| 5 | Common | Common Stock | 2026-03-07 | M | A | 1,585 | $0.00 | 12,882 | D | — | — | |
| 6 | Common | Common Stock | 2026-03-08 | F | D | 6,877 | $132.00 | 21,450 | D | — | — | |
| 7 | Derivative | Common Stock | 2026-03-08 | M | D | 2,153 | $0.00 | 6,908 | D | — · — to — | 2,153 Common Stock | (F2) These securities are Restricted Stock Units. (F3) There is neither a purchase price nor an exercise price for the Restricted Stock Units. (F4) One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date. (F5) These are restricted stock units that fully vest 3 years from the grant date. |
| 8 | Derivative | Performance Shares | 2026-03-07 | M | D | 1,585 | $0.00 | 3,170 | D | — · 2026-03-07 to — | 1,585 Common Stock | (F7) There is neither a purchase price nor an exercise price for the PRSUs. (F8) One-third of the shares shall vest on each of the first, second, and third anniversaries of the grant date. The vested shares shall become exercisable if, during the term of the option, the closing price of the Company's common stock is equal to or more than one-hundred and thirty percent of the exercise price per share for thirty consecutive trading days. The appreciation must occur within four years from the grant date. (F9) Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. If earned, these PRSUs vest on the first, second, and third year following the year of grant. |
| 9 | Derivative | Performance Shares | 2026-03-08 | M | D | 16,147 | $0.00 | 0 | D | $0.00 · 2026-03-08 to 2027-03-08 | 16,147 Common Stock | (F6) These Securities are Performance-based Restricted Stock Units (PRSU). (F1) Represents the settlement of performance stock units granted on 3/8/2024. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 250% of target, resulting in the acquisition of the shares reported herein. (F7) There is neither a purchase price nor an exercise price for the PRSUs. |